Amarin Corporation/$AMRN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Amarin Corporation
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Ticker
$AMRN
Sector
Primary listing
Employees
-
Headquarters
Dublin, Ireland
Website
AMRN Metrics
BasicAdvanced
$337M
-
-$4.19
0.63
-
Price and volume
Market cap
$337M
Beta
0.63
52-week high
$20.90
52-week low
$8.32
Average daily volume
141K
Financial strength
Current ratio
3.448
Quick ratio
2.271
Long term debt to equity
1.467
Total debt to equity
1.968
Interest coverage (TTM)
-3,961.14%
Profitability
EBITDA (TTM)
-24.665
Gross margin (TTM)
54.96%
Net profit margin (TTM)
-38.01%
Operating margin (TTM)
-12.23%
Effective tax rate (TTM)
-1.28%
Management effectiveness
Return on assets (TTM)
-2.46%
Return on equity (TTM)
-17.41%
Valuation
Price to revenue (TTM)
1.479
Price to book
0.73
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-15.343
Free cash flow yield (TTM)
-6.52%
Free cash flow per share (TTM)
-1.057
Growth
Revenue change (TTM)
-5.93%
Earnings per share change (TTM)
109.25%
3-year revenue growth (CAGR)
-18.80%
10-year revenue growth (CAGR)
12.22%
3-year earnings per share growth (CAGR)
-3.16%
10-year earnings per share growth (CAGR)
-12.80%
Bulls say / Bears say
Third quarter 2025 total net revenue increased 17% year-over-year to $49.7 million, driven by a 34% surge in U.S. net product revenue due to regained exclusivity with a major PBM (Amarin).
Entered an exclusive long-term license and supply agreement with Recordati, receiving $25 million upfront, potential milestone payments up to $150 million and $70 million in cost savings over 12 months, bolstering liquidity and accelerating the path to positive free cash flow (GlobeNewswire).
Initiated commercial launch of VAZKEPA in Germany, the first European market, leveraging ESC guideline inclusion and clinical data to expand patient access and diversify revenue streams (Amarin).
Total net revenue for the six months ended June 30, 2025 declined 7% year-over-year to $114.8 million, reflecting top-line pressure from U.S. sales erosion and delayed international revenue ramp (SEC 10-Q).
U.S. net product revenue plummeted 21% year-over-year to $72.2 million in H1 2025 due to generic competition and loss of a key national PBM exclusive contract (SEC 10-Q).
The U.S. Court of Appeals invalidated six Vascepa patents, opening the door to increased generic competition and further pressure on U.S. market share (Bloomberg Law).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amarin Corporation stock?
Amarin Corporation (AMRN) has a market cap of $337M as of November 13, 2025.
What is the P/E ratio for Amarin Corporation stock?
The price to earnings (P/E) ratio for Amarin Corporation (AMRN) stock is 0 as of November 13, 2025.
Does Amarin Corporation stock pay dividends?
No, Amarin Corporation (AMRN) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Amarin Corporation dividend payment date?
Amarin Corporation (AMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Amarin Corporation?
Amarin Corporation (AMRN) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.